TL;DR
- Mild prolactin elevation is common on feminising HRT, particularly with cyproterone acetate (CPA)
- CPA-induced hyperprolactinaemia is well-established; the mechanism likely involves progestogenic effects on pituitary lactotrophs and altered dopaminergic regulation
- Spironolactone-based regimens are associated with little or no clinically meaningful prolactin increase
- Marked elevations or symptoms (galactorrhoea, visual disturbance, persistent headache) warrant further evaluation
- Monitoring guidance has shifted toward individualised assessment — routine testing is less universally recommended than it once was, especially outside CPA use
Prolactin is a hormone produced by the pituitary gland. It is best known for stimulating milk production, but it has a wide range of other functions including roles in immune regulation and metabolism. Mild to moderate prolactin elevation is relatively common in trans women receiving feminising HRT, particularly when cyproterone acetate is used, and interpreting your result correctly requires understanding what is driving it.
Why prolactin rises on HRT
Oestrogen has modest stimulatory effects on prolactin secretion, but clinically significant elevations are much more strongly associated with cyproterone acetate. This oestrogen effect is a normal physiological one — prolactin rises during pregnancy partly due to high oestrogen levels. In trans women on feminising HRT, mild elevations in prolactin from oestrogen alone are common and expected.
The more significant driver, where it is used, is cyproterone acetate (CPA). CPA is a progestogenic antiandrogen used in many countries as part of feminising HRT. Its association with hyperprolactinaemia is well-established. In one prospective cohort, prolactin levels in trans women on CPA increased substantially within the first few months of treatment, rising from a mean of 150 mIU/L at baseline to 440 mIU/L by month 3. The proportion of individuals exceeding the upper limit of the female reference range also rose over time — from approximately 15% at 3 months to about 30% at 12 months. The mechanism is incompletely understood but likely involves progestogenic effects on pituitary lactotrophs and altered dopaminergic regulation.
Importantly, when CPA is stopped — such as after gonadectomy — prolactin levels typically return toward baseline, suggesting the elevation is drug-driven rather than pathological.
Spironolactone is different
In contrast to CPA, spironolactone-based regimens are associated with little or no clinically meaningful increase in prolactin. Studies specifically examining trans women on oestradiol and spironolactone have generally found no significant rise. Small increases have occasionally been observed, but the pattern is markedly different from CPA. If you are on a spironolactone-based regimen, routine prolactin monitoring is less clearly indicated, though clinical context still applies.
When to be concerned
Mildly elevated prolactin with no symptoms generally does not require further investigation beyond monitoring. Symptoms that warrant further evaluation include galactorrhoea (spontaneous milk discharge), visual field disturbance, persistent headaches, or prolactin rising markedly despite stable HRT.
Marked elevations — particularly when prolactin enters the several-thousand mIU/L range (often cited as above 2000–4000 mIU/L, though exact thresholds vary by assay) — warrant further evaluation, especially alongside symptoms or a progressively rising trend, although medications such as CPA can occasionally produce levels in this range without an underlying structural cause. There is no universally agreed single cutoff; clinical context, symptom profile, and trajectory matter as much as the number itself.
Prolactinoma (a benign pituitary tumour that secretes prolactin) is a rare but documented occurrence. Although oestrogen stimulates lactotroph proliferation experimentally, current clinical evidence does not demonstrate a clearly increased prolactinoma risk in trans women receiving standard oestradiol therapy at physiological doses.
Which reference range to use
This matters. Labs typically report prolactin against sex-assigned-at-birth reference ranges. The male reference range is lower than the female range. Prolactin results in trans women on HRT are generally interpreted against the female reference interval, which more accurately reflects their hormonal milieu. Always check which range your lab is applying to your result — the same number can look normal or elevated depending on which range is used.
Monitoring guidance
The 2017 Endocrine Society guideline recommended baseline prolactin measurement followed by annual testing and then every two years. More recent practice has shifted toward individualised monitoring, particularly because clinically significant hyperprolactinaemia appears uncommon outside cyproterone acetate use. WPATH SOC-8 did not issue a fixed monitoring schedule, deferring instead to individualised clinical decision-making.
Mild asymptomatic prolactin elevations are common in people taking CPA and usually do not require pituitary imaging. Serial monitoring and assessment for symptoms are generally sufficient, with further evaluation reserved for marked elevations or concerning clinical features.
⚠️ Clinical note: The prolactin thresholds cited are approximations and vary by assay and reporting units (mIU/L vs ng/mL). No single cutoff reliably distinguishes drug-induced hyperprolactinaemia from prolactinoma. Stress, venepuncture, exercise, sleep deprivation, and macroprolactin can also influence prolactin measurements and occasionally complicate interpretation. Interpretation should always incorporate clinical symptoms, medication history, and trend over time rather than relying on a single value.
Sources
- Defreyne J, Nota N, Pereira C, et al. Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment. LGBT Health. 2017;4(5):328–336.
- Bisson JR, Chan KJ, Safer JD. Prolactin Levels Do Not Rise Among Transgender Women Treated With Estradiol and Spironolactone. Endocrine Practice. 2018;24(7):646–651.
- Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T’Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2017;102(11):3869–3903.
- Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. 2022;23(S1):S1–S259.
